(Q37038988)

17 August 2017

1 reference

title

Therapeutic applications of aptamers (English)

1 reference

17 August 2017

Gurjot Kaur

1

1 reference

17 August 2017

Ipsita Roy

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 January 2008

1 reference

Expert Opinion on Investigational Drugs

17 August 2017

published in

1 reference

17 August 2017

volume

17

1 reference

17 August 2017

issue

1

1 reference

17 August 2017

page(s)

43-60

1 reference

Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Antisense oligonucleotides as a tool for gene functionalization and target validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

RNA interference: listening to the sound of silence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Review of the application of RNA interference technology in the pharmaceutical industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Prospects for antiviral ribozymes and deoxyribozymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Developing aptamers into therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Nucleic Acid Aptamers as Tools and Drugs: Recent Developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

A rapid in vitro method for obtaining RNA accessibility patterns for complementary DNA probes: correlation with an intracellular pattern and known RNA structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

2'-Modified oligonucleotides for antisense therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Oblimersen in the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Interfering with disease: a progress report on siRNA-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

In vitro splicing of the ribosomal RNA precursor of tetrahymena: Involvement of a guanosine nucleotide in the excision of the intervening sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Developments in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Antisense technologies. Improvement through novel chemical modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

RNA aptamers directed to discrete functional sites on a single protein structural domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

An RNA aptamer that interferes with the DNA binding of the HSF transcription activator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

RNA aptamers binding the double-stranded RNA-binding domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Coupling gene expression to cAMP signalling: role of CREB and CREM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Aptamer beacons for the direct detection of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Smart aptamers facilitate multi-probe affinity analysis of proteins with ultra-wide dynamic range of measured concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Protein detection using proximity-dependent DNA ligation assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Detection of proteins based on amino acid sequences by multiple aptamers against tripeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Detection of biomolecule by aptamer beacon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Molecular beacon aptamer fluoresces in the presence of Tat protein of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Adaptive recognition by nucleic acid aptamers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

In vitro selection of RNA molecules that bind specific ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

The joys of in vitro selection: chemically dressing oligonucleotides to satiate protein targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Current methods for the generation of human antibodies for the treatment of autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

mRNA display: diversity matters during in vitro selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

A novel technique for efficient construction of large scFv libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

In-vitro protein evolution by ribosome display and mRNA display

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

In vitro selection of RNA ligands to substance P.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Discriminatory aptamer reveals serum response element transcription regulated by cytohesin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

A new modified thrombin binding aptamer containing a 5'-5' inversion of polarity site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

RNA aptamers as reversible antagonists of coagulation factor IXa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Bioavailability of antisense oligonucleotides in neuroblastoma cells: comparison of efficacy among different types of molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Mechanisms and optimization of in vivo delivery of lipophilic siRNAs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

RNA aptamers as effective protein antagonists in a multicellular organism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

High interstitial fluid pressure - an obstacle in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Functional RNA microarrays for high-throughput screening of antiprotein aptamers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Aptamer:toxin conjugates that specifically target prostate tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Antiproliferative activity of G-rich oligonucleotides correlates with protein binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Biophysical and biological properties of quadruplex oligodeoxyribonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Antiproliferative activity of G-quartet-forming oligonucleotides with backbone and sugar modifications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Aptamers in the virologists' toolkit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Gene transfer in humans using a conditionally replicating lentiviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Aptamers directed to HIV-1 reverse transcriptase display greater efficacy over small hairpin RNAs targeted to viral RNA in blocking HIV-1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Mutations that confer resistance to template-analog inhibitors of human immunodeficiency virus (HIV) type 1 reverse transcriptase lead to severe defects in HIV replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Cross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Neutralization of Infectivity of Diverse R5 Clinical Isolates of Human Immunodeficiency Virus Type 1 by gp120-Binding 2′F-RNA Aptamers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

HIV-1 reverse transcriptase mutations that confer decreased in vitro susceptibility to anti-RT DNA aptamer RT1t49 confer cross resistance to other anti-RT aptamers but not to standard RT inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Active site binding and sequence requirements for inhibition of HIV-1 reverse transcriptase by the RT1 family of single-stranded DNA aptamers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

DNA aptamers selected against the HIV-1 RNase H display in vitro antiviral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Engineering of therapeutic antibodies to minimize immunogenicity and optimize function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Biostable aptamers with antagonistic properties to the neuropeptide nociceptin/orphanin FQ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Prevention of passively transferred experimental autoimmune myasthenia gravis by an in vitro selected RNA aptamer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Highly potent irreversible inhibitors of neutrophil elastase generated by selection from a randomized DNA-valine phosphonate library

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Targeting the variable surface of African trypanosomes with variant surface glycoprotein-specific, serum-stable RNA aptamers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Boron-containing aptamers to ATP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

Nucleolipoplexes: A New Paradigm for Phospholipid Bilayer−Nucleic Acid Interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.43

21 January 2018

Identifiers

DOI

10.1517/13543784.17.1.43

1 reference

17 August 2017

1 reference